menu
    • menu
    [{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"IMM-124E","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuron \/ Not Applicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Monash University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"IMM-124E","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuron \/ Monash University","highestDevelopmentStatusID":"4","companyTruncated":"Immuron \/ Monash University"},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM-124E","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immuron \/ Not Applicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Medical Technology Enterprise Consortium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"Bovine Colostrum","moa":"Enterotoxigenic Escherichia coli","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Medical Technology Enterprise Consortium","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ Medical Technology Enterprise Consortium"},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ Not Applicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM-529","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuron \/ Not Applicable"},{"orgOrder":0,"company":"Immuron","sponsor":"US Naval Medical Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Immuron \/ US Naval Medical Research Center","highestDevelopmentStatusID":"5","companyTruncated":"Immuron \/ US Naval Medical Research Center"},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bovine Colostrum","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuron \/ Not Applicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Pharmaron","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Bovine Colostrum","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Pharmaron","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ Pharmaron"},{"orgOrder":0,"company":"Immuron","sponsor":"Ateria Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"Bovine Colostrum","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Immuron","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ Immuron"},{"orgOrder":0,"company":"Immuron","sponsor":"Ateria Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"Bovine Colostrum","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Immuron","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ Immuron"},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bovine Colostrum","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ Not Applicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bovine Colostrum","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ Not Applicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Polyclonal Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuron \/ Not Applicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CampETEC","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immuron \/ Not Applicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Immuron","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CampETEC","moa":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Immuron \/ Immuron","highestDevelopmentStatusID":"5","companyTruncated":"Immuron \/ Immuron"},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Bovine Colostrum","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ Not Applicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Bovine Colostrum","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ Not Applicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Bovine Colostrum","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ Not Applicable"},{"orgOrder":0,"company":"Immuron","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"Bovine Colostrum","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ U.S. Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Immuron \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Immuron","sponsor":"US Naval Medical Research Command","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"CampETEC","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Immuron \/ US Naval Medical Research Command","highestDevelopmentStatusID":"6","companyTruncated":"Immuron \/ US Naval Medical Research Command"},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"IMM-529","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ Not Applicable"},{"orgOrder":0,"company":"Immuron","sponsor":"NMRC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Bovine Colostrum","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Immuron \/ NMRC","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ NMRC"},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"CampETEC","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Immuron

    Menu

    Immuron

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CampETEC

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

                            Details : Immuron vaccine drug candidate CampETEC, is being evaluating for the diarrhoea caused by Campylobacter and including Enterotoxigenic Escherichia coli infections.

                            Brand Name : CampETEC

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            October 04, 2024

                            Lead Product(s) : CampETEC

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMM-529

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immuron Plans Phase 2 Trial for IMM-529 following FDA Review

                            Details : IMM-529 is a polyclonal antibody bein investigated for Clostridioides difficile infections as it neutralises localized toxin B at the site of infection.

                            Brand Name : IMM-529

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 05, 2024

                            Lead Product(s) : IMM-529

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bovine Colostrum

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : NMRC

                            Deal Size : $2.3 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Immuron Wins U.S. DoD Award to Advance Travelan with Naval Medical Research Command

                            Details : The focus of the agreement is to develop an enhanced formulation of Travelan (bovine colostrum) to cover the product as a therapeutic measure against endemic military relevant diarrheal pathogens.

                            Brand Name : Travelan

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 16, 2024

                            Lead Product(s) : Bovine Colostrum

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : NMRC

                            Deal Size : $2.3 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bovine Colostrum

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : U.S. Department of Defense

                            Deal Size : $3.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Immuron Announces Positive Travelan® Results for US Phase 3 Trials

                            Details : The funding aims to support Immuron advance their clinical development of Travelan (bovine colostrum), which is being evaluated in Phase II clinical trial studies for moderate to severe diarrhea.

                            Brand Name : Travelan

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 07, 2024

                            Lead Product(s) : Bovine Colostrum

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : U.S. Department of Defense

                            Deal Size : $3.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CampETEC

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : US Naval Medical Research Command

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

                            Details : Immuron vaccine drug candidate CampETEC, which is being evaluating for the diarrhoea caused by Campylobacter and including Enterotoxigenic Escherichia coli infections.

                            Brand Name : CampETEC

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            December 04, 2023

                            Lead Product(s) : CampETEC

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : US Naval Medical Research Command

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bovine Colostrum

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immuron Announces Travelan® Clinical Study Cohort 2 Commences

                            Details : Travelan (bovine colostrum) is an oral biopharmaceutical product that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract, to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC).

                            Brand Name : Travelan

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 18, 2023

                            Lead Product(s) : Bovine Colostrum

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bovine Colostrum

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immuron Announces First Patients Enrolled in Travelan® Clinical Study

                            Details : Travelan (bovine colostrum) is an oral biopharmaceutical product that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract, to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC).

                            Brand Name : Travelan

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 25, 2023

                            Lead Product(s) : Bovine Colostrum

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bovine Colostrum

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immuron Initiates Recruitment of Travelan® Clinical Study

                            Details : Travelan (bovine colostrum) is an oral biopharmaceutical product that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract, to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC).

                            Brand Name : Travelan

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 30, 2023

                            Lead Product(s) : Bovine Colostrum

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CampETEC

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Recipient : Naval Medical Research Center

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial...

                            Details : CampETEC is a new therapeutic developed in collaboration with NMRC. Two Phase Il clinical studies are planned to evaluate safety and clinical efficacy against infectious diarrhea caused by Campylobacter and ETEC.

                            Brand Name : CampETEC

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 08, 2023

                            Lead Product(s) : CampETEC

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Recipient : Naval Medical Research Center

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Immuron

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CampETEC

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeu...

                            Details : The Naval Medical Research Center (NMRC) has executed a research agreement with Immuron to develop and clinically evaluate a new therapeutic CampETEC, targeting Campylobacter and ETEC infections.

                            Brand Name : CampETEC

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 25, 2023

                            Lead Product(s) : CampETEC

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth